In the last trading session, 0.14 million LENZ Therapeutics Inc (NASDAQ:LENZ) shares changed hands as the company’s beta touched 0.64. With the company’s per share price at $32.30 changed hands at $1.0 or 3.19% during last session, the market valuation stood at $866.28M. LENZ’s last price was a discount, traded about -20.53% off its 52-week high of $38.93. The share price had its 52-week low at $11.31, which suggests the last value was 64.98% up since then. When we look at LENZ Therapeutics Inc’s average trading volume, we note the 10-day average is 0.21 million shares, with the 3-month average coming to 163.23K.
Analysts gave the LENZ Therapeutics Inc (LENZ) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.14. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LENZ as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. LENZ Therapeutics Inc’s EPS for the current quarter is expected to be -0.4.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
LENZ Therapeutics Inc (NASDAQ:LENZ) trade information
Instantly LENZ was in green as seen at the end of in last trading. With action -2.81%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 154.04%, with the 5-day performance at -2.81% in the red. However, in the 30-day time frame, LENZ Therapeutics Inc (NASDAQ:LENZ) is -11.27% down. Looking at the short shares, we see there were 2.27 million shares sold at short interest cover period of 14.91 days.
The consensus price target for the stock as assigned by Wall Street analysts is 34, meaning bulls need an upside of 5.0% from its current market value. According to analyst projections, LENZ’s forecast low is 32 with 36 as the target high. To hit the forecast high, the stock’s price needs a -11.46% plunge from its current level, while the stock would need to tank 0.93% for it to hit the projected low.
The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -483.52%. The 2024 estimates are for LENZ Therapeutics Inc earnings to increase by 65.49%, but the outlook for the next 5-year period is at 38.53% per year.
LENZ Dividends
LENZ Therapeutics Inc is expected to release its next quarterly earnings report in January. The 0.00% annual yield figure for the share gives it an annual dividend of 0.00. It is important to note, however, that the 0.00% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision.
